Fluticasone Furoate, Umeclidinium Bromide and Vilanterol TrifenatatePowder for Inhalation

Fluticasone inhalation powder is suitable for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Fluticasone is a triple inhalation preparation, a compound preparation composed of fluticasone furoate, umeclidinium bromide and vilanterol triphenylacetate. This product is used once a day and has the advantages of rapid onset, long duration of action, liver metabolism and low toxicity.
Fluticasone furoate: It can effectively inhibit the release of inflammatory mediators and the transcription of inflammatory cytokines, inhibiting inflammatory response.
Umeclidinium bromide: It can competitively inhibit the binding of acetylcholine to M3 muscarinic receptors on respiratory smooth muscle, dilate bronchi, and relieve patients’ shortness of breath, wheezing and other symptoms.
Vilanterol: It is a long-acting β2 receptor agonist that can activate adenylate cyclase in cells, catalyze the conversion of adenosine triphosphate, increase the level of cyclic adenosine monophosphate, relax bronchial smooth muscle and inhibit the release of inflammatory mediators.